Results

You'll meet with your cancer doctor (oncologist) regularly for follow-up visits while you're taking hormone therapy for breast cancer. Your oncologist will ask about any side effects you're experiencing. Many side effects can be controlled.

Hormone therapy following surgery, radiation or chemotherapy has been shown to reduce the risk of breast cancer recurrence in people with early-stage hormone-sensitive breast cancers. It can also effectively reduce the risk of metastatic breast cancer growth and progression in people with hormone-sensitive tumors.

Depending on your circumstances, you may undergo tests to monitor your medical situation and watch for cancer recurrence or progression while you're taking hormone therapy. Results of these tests can give your doctor an idea of how you're responding to hormone therapy, and your therapy may be adjusted accordingly.

Sept. 01, 2017
References
  1. Breast cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 5, 2016.
  2. Hormone therapy for breast cancer. National Cancer Institute. http://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. Accessed Aug. 19, 2016.
  3. Pritchard KI. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer. http://www.uptodate.com/home. Accessed Aug. 19, 2016.
  4. Fareston (prescribing information). Bridgewater, N.J.: ProStrakan Inc.; 2012. http://www.fareston.com. Accessed Aug. 19, 2016.
  5. Arimidex (prescribing information). Wilmington, Del.: AstraZeneca; 2013. http://www.arimidex.com. Accessed Aug. 19, 2016.
  6. Aromasin (prescribing information). New York, N.Y.: Pfizer Inc.; 2016. http://www.aromasin.com. Accessed Aug. 19, 2016.
  7. Faslodex (prescribing information). Wilmington, Del.: AstraZeneca; 2017. http://www.faslodex.com. Accessed Aug. 28, 2017.
  8. Zoladex (prescribing information). Wilmington, Del.: AstraZeneca; 2016. http://www.zoladex.com. Accessed Aug. 19, 2016.
  9. Femara (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2014. http://www.femara.com. Accessed Aug. 19, 2016.
  10. AskMayoExpert. Breast cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  11. Ellis M, et al. Mechanisms of action of selective estrogen receptor modulators. http://www.uptodate.com/home. Accessed Sept. 12, 2016.
  12. Ibrance (prescribing information). Mission, Kan.: Pfizer Inc; 2016. http://www.ibrance.com. Accessed Sept. 12, 2016.
  13. Afinitor (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2016. http://www.afinitor.com. Accessed Sept. 12, 2016.